YD Bio Ltd (YDES)

Data as of Oct 6, 2026, from SEC Form 4 filings.

Net insider buying (90d)Watch YDES

See up to 3 months of YDES. The 7-day demo opens the 1M and 3M ranges and puts YDES on your watchlist.

Latest YDES insider trades

Ethan Phd Shen - Officer
Open-market purchase$49K
Sep 14, 2026
Ethan Phd Shen - Officer
Open-market purchase$12K
Sep 9, 2026
Ethan Phd Shen - Officer

About YD Bio Ltd (YDES)

YD Bio Ltd files with the SEC under CIK 0002011674 and is classified as medical laboratories. It is grouped with Health Care companies on this site.

Sector: Health Care

SEC filings for YDES on EDGAR

YDES Form 4 activity by transaction type, last 90 days

Form 4 transaction type	Transactions	Shares	Total value
Open-market purchase	3	34,178	$129K
Grant or award	2	6,270
Option exercise	4	12,540

Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.

YDES insider transactions (Form 4)

9 Form 4 filings on record, the earliest from Apr 2, 2026, newest first.

Date	Insider	Transaction	Security	Shares	Price	Value
Sep 30, 2026	Kochi Chang - Director	Option exercise	Ordinary Shares	3,135	-^{footnote F1}	-
Sep 30, 2026	Kochi Chang - Director	Grant or award	Restricted Share Units	3,135^{footnote F2,F3}	$0.00	-
Sep 30, 2026	Kochi Chang - Director	Option exercise	Restricted Share Units	3,135	$0.00	-
Footnote F1 (price): Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Shares"), of YD Bio Limited. Footnote F2 (shares): The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning March 31, 2026, with the number of… Full note on SEC EDGAR Footnote F3 (shares): The Reporting Person became entitled to a fixed number of RSUs on September 30, 2026 (the "Vesting Date").
Sep 30, 2026	Shao-Ta Lu - Director	Option exercise	Ordinary Shares	3,135	-^{footnote F1}	-
Sep 30, 2026	Shao-Ta Lu - Director	Grant or award	Restricted Share Units	3,135^{footnote F2,F3}	$0.00	-
Sep 30, 2026	Shao-Ta Lu - Director	Option exercise	Restricted Share Units	3,135	$0.00	-
Footnote F1 (price): Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Shares"), of YD Bio Limited. Footnote F2 (shares): The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning March 31, 2026, with the number of… Full note on SEC EDGAR Footnote F3 (shares): The Reporting Person became entitled to a fixed number of RSUs on September 30, 2026 (the "Vesting Date").
Sep 14, 2026	Ethan Phd Shen - Officer	Open-market purchase	Ordinary Shares	12,700	$3.85^{footnote F1}	$49K
Footnote F1 (price): The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.67 to $3.97, inclusive. The reporting person undertakes to provide to YD Bio Ltd (the "Company"), any security holder of the Company or the staff… Full note on SEC EDGAR
Sep 9, 2026	Ethan Phd Shen - Officer	Open-market purchase	Ordinary Shares	3,100	$3.93^{footnote F1}	$12K
Footnote F1 (price): The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.80 to $4.09, inclusive. The reporting person undertakes to provide to YD Bio Ltd (the "Company"), any security holder of the Company or the staff… Full note on SEC EDGAR
Sep 4, 2026	Ethan Phd Shen - Officer	Open-market purchase	Ordinary Shares	18,378	$3.67^{footnote F1}	$67K
Footnote F1 (price): The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.50 to $3.70, inclusive. The reporting person undertakes to provide to YD Bio Ltd (the "Company"), any security holder of the Company or the staff… Full note on SEC EDGAR
Jun 30, 2026	Shao-Ta Lu - Director	Option exercise	Ordinary Shares	5,749	-^{footnote F1}	-
Jun 30, 2026	Shao-Ta Lu - Director	Grant or award	Restricted Share Units	5,749^{footnote F2,F3}	$0.00	-
Jun 30, 2026	Shao-Ta Lu - Director	Option exercise	Restricted Share Units	5,749	$0.00	-
Footnote F1 (price): Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Shares"), of YD Bio Limited. Footnote F2 (shares): The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning March 31, 2026, with the number of… Full note on SEC EDGAR Footnote F3 (shares): The Reporting Person became entitled to a fixed number of RSUs on June 30, 2026 (the "Vesting Date").
Jun 30, 2026	Kochi Chang - Director	Option exercise	Ordinary Shares	5,749	-^{footnote F1}	-
Jun 30, 2026	Kochi Chang - Director	Grant or award	Restricted Share Units	5,749^{footnote F2,F3}	$0.00	-
Jun 30, 2026	Kochi Chang - Director	Option exercise	Restricted Share Units	5,749	$0.00	-
Footnote F1 (price): Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Shares"), of YD Bio Limited. Footnote F2 (shares): The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning March 31, 2026, with the number of… Full note on SEC EDGAR Footnote F3 (shares): The Reporting Person became entitled to a fixed number of RSUs on June 30, 2026 (the "Vesting Date").
Mar 31, 2026	Shao-Ta Lu - Director	Option exercise	Ordinary Shares	2,081	-^{footnote F1}	-
Mar 31, 2026	Shao-Ta Lu - Director	Grant or award	Restricted Share Units	2,081^{footnote F2,F3}	$0.00	-
Mar 31, 2026	Shao-Ta Lu - Director	Option exercise	Restricted Share Units	2,081	$0.00	-
Footnote F1 (price): Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Share"), of YD Bio Limited. Footnote F2 (shares): The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning on March 31, 2026, with the number of… Full note on SEC EDGAR Footnote F3 (shares): The Reporting Person became entitled to a fixed number of RSUs on March 31, 2026 (the "Vesting Date").
Mar 31, 2026	Kochi Chang - Director	Option exercise	Ordinary Shares	2,081	-^{footnote F1}	-
Mar 31, 2026	Kochi Chang - Director	Grant or award	Restricted Share Units	2,081^{footnote F2,F3}	$0.00	-
Mar 31, 2026	Kochi Chang - Director	Option exercise	Restricted Share Units	2,081	$0.00	-
Footnote F1 (price): Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Share"), of YD Bio Limited. Footnote F2 (shares): The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning on March 31, 2026, with the number of… Full note on SEC EDGAR Footnote F3 (shares): The Reporting Person became entitled to a fixed number of RSUs on March 31, 2026 (the "Vesting Date").

YDES insider trading FAQ

What is the latest insider trade for YDES?

YD Bio Ltd (YDES) had 5 insider filings in the last 90 days, with the most recent on 2026-10-06. The full record for YDES runs to 9 Form 4 filings, the earliest from 2026-04-02. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.

How many insiders are buying YDES stock?

3 insider purchases of YDES were filed in the last 90 days, totaling $129K.

How many insiders are selling YDES stock?

No insider sales of YDES were filed in the last 90 days.

Where can I see YDES SEC filings (Form 4, 10-K, 10-Q, 8-K)?

This page collects YDES Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.

More Health Care companies with insider activity

Recent insider filings

The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.

Oct 6, 2026 - Kochi Chang view on EDGAR
Oct 6, 2026 - Shao-Ta Lu view on EDGAR
Sep 16, 2026 - Ethan Phd Shen view on EDGAR
Sep 10, 2026 - Ethan Phd Shen view on EDGAR
Sep 8, 2026 - Ethan Phd Shen view on EDGAR
Jul 1, 2026 - Shao-Ta Lu view on EDGAR
Jul 1, 2026 - Kochi Chang view on EDGAR
Apr 2, 2026 - Shao-Ta Lu view on EDGAR
Apr 2, 2026 - Kochi Chang view on EDGAR

Related companies with recent insider activity

Learn more

How to read insider buying signals: What an open-market purchase by an insider can and cannot tell you.
Insider activity in Health Care: Where YDES's peers are being bought and sold.
Every recent Form 4: The market-wide feed, updated as filings arrive from SEC EDGAR.

Follow YDES with a 7-day demo

YDES on your watchlist
Every YDES Form 4 filing on record
Up to 3 months of YDES price history
The daily trading plan of ranked insider buys, on a delay, with the plan archive

Start 7-day demoCard required. Your card is never charged for the demo.

Form 4 transaction type

Transactions

Total value

Open-market purchase

34,178

$129K

Grant or award

6,270

Option exercise

12,540

Date

Insider

Transaction

Security

Price

Value

Sep 30, 2026

Kochi Chang - Director

Option exercise

Ordinary Shares

3,135

-^{footnote F1}

Sep 30, 2026

Kochi Chang - Director

Grant or award

Restricted Share Units

3,135^{footnote F2,F3}

$0.00

Sep 30, 2026

Kochi Chang - Director

Option exercise

Restricted Share Units

3,135

$0.00

Footnote F1 (price): Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Shares"), of YD Bio Limited.
Footnote F2 (shares): The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning March 31, 2026, with the number of… Full note on SEC EDGAR
Footnote F3 (shares): The Reporting Person became entitled to a fixed number of RSUs on September 30, 2026 (the "Vesting Date").

Sep 30, 2026

Shao-Ta Lu - Director

Option exercise

Ordinary Shares

3,135

-^{footnote F1}

Sep 30, 2026

Shao-Ta Lu - Director

Grant or award

Restricted Share Units

3,135^{footnote F2,F3}

$0.00

Sep 30, 2026

Shao-Ta Lu - Director

Option exercise

Restricted Share Units

3,135

$0.00

Footnote F1 (price): Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Shares"), of YD Bio Limited.
Footnote F2 (shares): The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning March 31, 2026, with the number of… Full note on SEC EDGAR
Footnote F3 (shares): The Reporting Person became entitled to a fixed number of RSUs on September 30, 2026 (the "Vesting Date").

Sep 14, 2026

Ethan Phd Shen - Officer

Open-market purchase

Ordinary Shares

12,700

$3.85^{footnote F1}

$49K

Footnote F1 (price): The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.67 to $3.97, inclusive. The reporting person undertakes to provide to YD Bio Ltd (the "Company"), any security holder of the Company or the staff… Full note on SEC EDGAR

Sep 9, 2026

Ethan Phd Shen - Officer

Open-market purchase

Ordinary Shares

3,100

$3.93^{footnote F1}

$12K

Footnote F1 (price): The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.80 to $4.09, inclusive. The reporting person undertakes to provide to YD Bio Ltd (the "Company"), any security holder of the Company or the staff… Full note on SEC EDGAR

Sep 4, 2026

Ethan Phd Shen - Officer

Open-market purchase

Ordinary Shares

18,378

$3.67^{footnote F1}

$67K

Footnote F1 (price): The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.50 to $3.70, inclusive. The reporting person undertakes to provide to YD Bio Ltd (the "Company"), any security holder of the Company or the staff… Full note on SEC EDGAR

Jun 30, 2026

Shao-Ta Lu - Director

Option exercise

Ordinary Shares

5,749

-^{footnote F1}

Jun 30, 2026

Shao-Ta Lu - Director

Grant or award

Restricted Share Units

5,749^{footnote F2,F3}

$0.00

Jun 30, 2026

Shao-Ta Lu - Director

Option exercise

Restricted Share Units

5,749

$0.00

Footnote F1 (price): Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Shares"), of YD Bio Limited.
Footnote F2 (shares): The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning March 31, 2026, with the number of… Full note on SEC EDGAR
Footnote F3 (shares): The Reporting Person became entitled to a fixed number of RSUs on June 30, 2026 (the "Vesting Date").

Jun 30, 2026

Kochi Chang - Director

Option exercise

Ordinary Shares

5,749

-^{footnote F1}

Jun 30, 2026

Kochi Chang - Director

Grant or award

Restricted Share Units

5,749^{footnote F2,F3}

$0.00

Jun 30, 2026

Kochi Chang - Director

Option exercise

Restricted Share Units

5,749

$0.00

Footnote F1 (price): Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Shares"), of YD Bio Limited.
Footnote F2 (shares): The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning March 31, 2026, with the number of… Full note on SEC EDGAR
Footnote F3 (shares): The Reporting Person became entitled to a fixed number of RSUs on June 30, 2026 (the "Vesting Date").

Mar 31, 2026

Shao-Ta Lu - Director

Option exercise

Ordinary Shares

2,081

-^{footnote F1}

Mar 31, 2026

Shao-Ta Lu - Director

Grant or award

Restricted Share Units

2,081^{footnote F2,F3}

$0.00

Mar 31, 2026

Shao-Ta Lu - Director

Option exercise

Restricted Share Units

2,081

$0.00

Footnote F1 (price): Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Share"), of YD Bio Limited.
Footnote F2 (shares): The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning on March 31, 2026, with the number of… Full note on SEC EDGAR
Footnote F3 (shares): The Reporting Person became entitled to a fixed number of RSUs on March 31, 2026 (the "Vesting Date").

Mar 31, 2026

Kochi Chang - Director

Option exercise

Ordinary Shares

2,081

-^{footnote F1}

Mar 31, 2026

Kochi Chang - Director

Grant or award

Restricted Share Units

2,081^{footnote F2,F3}

$0.00

Mar 31, 2026

Kochi Chang - Director

Option exercise

Restricted Share Units

2,081

$0.00

Footnote F1 (price): Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Share"), of YD Bio Limited.
Footnote F2 (shares): The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning on March 31, 2026, with the number of… Full note on SEC EDGAR
Footnote F3 (shares): The Reporting Person became entitled to a fixed number of RSUs on March 31, 2026 (the "Vesting Date").